Beactica, KU Leuven Secure EIC Grant for BEA-17

Beactica Therapeutics AB, a Swedish precision medicine company, in collaboration with KU Leuven, has been awarded a EUR 2.5 million grant by the International===European Innovation Council. This funding, secured through the highly competitive EIC Transition program, will advance BEA-17, Beactica Therapeutics AB's wholly owned, first-in-class precision immune therapy for glioblastoma. The 30-month GLIOBREAK project aims to progress BEA-17 from a validated laboratory stage to early clinical readiness, including the completion of IND-enabling studies and submission of a regulatory application to either the United States===Food and Drug Administration or International===European Medicines Agency. BEA-17, which has already received Orphan Drug Designation from the United States===Food and Drug Administration, targets the epigenetic protein complex LSD1-CoREST and has shown promising results in preclinical models. This grant is crucial for bringing this innovative treatment closer to patients suffering from glioblastoma, an aggressive brain tumor with limited effective treatments.